Evogene Sets New Course with AI-driven ChemPass Strategy and Plans for Future Collaborations

jueves, 5 de marzo de 2026, 4:53 pm ET1 min de lectura
EVGN--

Evogene is undergoing a strategic transformation, focusing on designing small molecules for drug development and agricultural chemicals using its ChemPass AI-driven strategy. CEO Ofer Haviv emphasized the company's deliberate choice to sharpen its focus and execution. Evogene anticipates new collaborations as it realigns its organization.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios